William Schuyler Jones

William Schuyler Jones

Associate Professor of Medicine

I am an interventional cardiologist with a specific focus on the diagnosis and treatment of patients with cardiovascular disease. As a clinician, I see patients in the office and do coronary and peripheral vascular procedures (angiography and interventions) in the Duke Cardiac Catheterization Laboratory. I have served as the Medical Director of the cath lab at Duke since 2016. Alongside my partners in the cath lab, we collaborate with our cardiothoracic surgeons to hold Heart Team meetings each week, and we frequently are asked to address complex cardiovascular issues as a multidisciplinary team.

I also have a broad background in cardiovascular site-based research, multicenter clinical trials, clinical event classification, and observational analyses. I have helped to lead clinical trial efforts at the Duke Clinical Research Institute (DCRI) by designing and conducting studies evaluating new and existing treatments for patients with coronary artery disease and peripheral artery disease. My specific research interests include examining access to care and disparities in care for patients with peripheral artery disease and the design and conduct of pragmatic clinical trials in cardiovascular disease.

Appointments and Affiliations

  • Associate Professor of Medicine
  • Associate Professor in Population Health Sciences
  • Member in the Duke Clinical Research Institute

Contact Information

  • Office Location: 2400 Pratt Street, 7037, Durham, NC 27705
  • Office Phone: +1 919 668 8917
  • Email Address: schuyler.jones@duke.edu

Education

  • Duke University, 2005
  • Duke University, 2004
  • M.D. University of Arkansas, Little Rock, 2001

Representative Publications

  • Edmonston, D; Mulder, H; Lydon, E; Chiswell, K; Lampron, Z; Shay, C; Marsolo, K; Jones, WS; Butler, J; Shah, RC; Chamberlain, AM; Ford, DE; Gordon, HS; Hwang, W; Chang, A; Rao, A; Bosworth, HB; Pagidipati, N, Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes., Am J Cardiol, vol 221 (2024), pp. 52-63 [10.1016/j.amjcard.2024.04.011] [abs].
  • Udell, JA; Petrie, MC; Jones, WS; Anker, SD; Harrington, J; Mattheus, M; Seide, S; Amir, O; Bahit, MC; Bauersachs, J; Bayes-Genis, A; Chen, Y; Chopra, VK; Figtree, G; Ge, J; Goodman, SG; Gotcheva, N; Goto, S; Gasior, T; Jamal, W; Januzzi, JL; Jeong, MH; Lopatin, Y; Lopes, RD; Merkely, B; Martinez-Traba, M; Parikh, PB; Parkhomenko, A; Ponikowski, P; Rossello, X; Schou, M; Simic, D; Steg, PG; Szachniewicz, J; van der Meer, P; Vinereanu, D; Zieroth, S; Brueckmann, M; Sumin, M; Bhatt, DL; Hernandez, AF; Butler, J, Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction., J Am Coll Cardiol, vol 83 no. 23 (2024), pp. 2233-2246 [10.1016/j.jacc.2024.03.405] [abs].
  • Hernandez, AF; Udell, JA; Jones, WS; Anker, SD; Petrie, MC; Harrington, J; Mattheus, M; Seide, S; Zwiener, I; Amir, O; Bahit, MC; Bauersachs, J; Bayes-Genis, A; Chen, Y; Chopra, VK; A Figtree, G; Ge, J; G Goodman, S; Gotcheva, N; Goto, S; Gasior, T; Jamal, W; Januzzi, JL; Jeong, MH; Lopatin, Y; Lopes, RD; Merkely, B; Parikh, PB; Parkhomenko, A; Ponikowski, P; Rossello, X; Schou, M; Simic, D; Steg, PG; Szachniewicz, J; van der Meer, P; Vinereanu, D; Zieroth, S; Brueckmann, M; Sumin, M; Bhatt, DL; Butler, J, Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial., Circulation, vol 149 no. 21 (2024), pp. 1627-1638 [10.1161/CIRCULATIONAHA.124.069217] [abs].
  • Rymer, JA; Narcisse, DI; Chen, A; Wojdyla, D; Ashley, S; Damluji, AA; Shah, B; Nanna, MG; Swaminathan, R; Gutierrez, JA; Uzendu, A; Nelson, AJ; Bethel, G; Kearney, K; Jones, WS; Rao, SV; Doll, JA, Case Volumes and Outcomes Among Early-Career Interventional Cardiologists in the United States., J Am Coll Cardiol, vol 83 no. 20 (2024), pp. 1990-1998 [10.1016/j.jacc.2024.03.395] [abs].
  • Usman, MS; Bhatt, DL; Hameed, I; Anker, SD; Cheng, AYY; Hernandez, AF; Jones, WS; Khan, MS; Petrie, MC; Udell, JA; Friede, T; Butler, J, Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis., Lancet Diabetes Endocrinol (2024) [10.1016/S2213-8587(24)00102-5] [abs].